Orchid Pharma's authorized share capital has been formally adjusted to ₹164.51 crore following its amalgamation with Dhanuka Laboratories. The merger is effective July 10, 2026, with a share exchange ratio of 161:5.
Orchid Pharma Amalgamation Completes: Share Capital Restructured
Orchid Pharma's authorized share capital is now ₹164.51 crore, comprising 16,45,10,000 equity shares of ₹10 face value each. This follows the formal conclusion of the amalgamation with Dhanuka Laboratories Limited (DLL).
Reader Takeaway: Shareholder structure changes significantly; integration is now legally effective.
What just happened
Orchid Pharma Ltd has formally adjusted its authorized share capital following the successful amalgamation with Dhanuka Laboratories Limited (DLL). The company's new authorized share capital stands at ₹164.51 crore, represented by 16,45,10,000 equity shares with a face value of ₹10 each.
This adjustment amends Clause V of Orchid Pharma's Memorandum of Association to reflect the combined share capital of both entities post-amalgamation.
Why this matters
This formal restructuring marks the legal completion of the merger process. It signifies that the integration of Dhanuka Laboratories into Orchid Pharma is now binding. The key dates provide clarity for shareholders regarding the transition and their eligibility for new shares.
For investors, this means a change in the company's equity structure and authorized capital, impacting future financial calculations and share consolidation.
The backstory
While the amalgamation's effective date is July 10, 2026, the accounting perspective for this integration began on April 1, 2024 (appointed date).
The merger scheme was approved to combine the operations and capital bases of both companies.
What changes now
The most immediate change is the formal legal recognition of the combined share capital. Shareholders of Dhanuka Laboratories are key to this transition.
They will receive 161 Orchid Pharma shares for every 5 Dhanuka Laboratories shares they hold, based on the record date of July 23, 2026.
Risks to watch
Shareholders of Dhanuka Laboratories need to monitor the record date closely to ensure eligibility for the share swap. Any delays or issues in the share allotment process could cause concern.
Investors should also track how the integrated entity performs financially and operationally going forward.
Peer comparison
Amalgamations and mergers are common in the pharmaceutical sector as companies seek to consolidate, expand market reach, and achieve operational efficiencies.
This move by Orchid Pharma aligns with industry trends aimed at strengthening market position.
Context metrics (time-bound)
- Effective Date: July 10, 2026
- Appointed Date (for accounting): April 1, 2024
- Record Date for share allotment: July 23, 2026
- Share Exchange Ratio: 161 Orchid Pharma shares for every 5 Dhanuka Laboratories shares
What to track next
Investors should look out for the official share allotment post the record date. Tracking the integrated company's financial performance and strategic announcements will be crucial.